Relevant bibliographies by topics / Tumore renale

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Tumore renale'

Author: Grafiati
Published: 9 March 2023
Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Tumore renale.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Tumore renale"

1

Fandella, A., P. Checchin, L. Maccatrozzo, F. Merlo, L. Faggiano, D. Frezza, G. Cescon, R. Kirn, M. C. DA Mosto, and C. Marchiori. "Epistassi Segno Rivelatore Isolato Di Tumore Renale." Urologia Journal 58, no. 1 (February 1991): 105–6. http://dx.doi.org/10.1177/039156039105800124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lusardi, Paola. "Cardiotossicità da ormonoterapia nel tumore della prostata." Cardiologia Ambulatoriale, no. 3 (November 30, 2020): 195–97. http://dx.doi.org/10.17473/1971-6818-2020-3-10.

Full text
Abstract:
Nel sesso maschile il tumore della prostata è il più rappresentato, ma la sopravvivenza a 10 anni dalla diagnosi è estremamente elevata (fino al 90%), sia per la diagnosi molto precoce attuata con le politiche di screening, sia per le elevate percentuali di malattia a rischio basso ed intermedio. La prognosi favorevole del tumore prostatico fa sì che il numero di comorbilità, quali dislipidemia, ipertensione, obesità, insufficienza renale cronica, cardiopatia ischemica e diabete, sia determinante sull’iter dei lungo sopravviventi. La terapia di deprivazione androgenica (ADT), che viene utilizzata nel setting terapeutico e palliativo, può essere considerata un fattore di rischio cardiovascolare aggiuntivo, in grado di accelerare i processi aterosclerotici sistemici e predisporre alla malattia coronarica e cerebrovascolare. Tutti i pazienti candidati o in trattamento con ADT devono pertanto essere valutati dal punto di vista cardiovascolare e metabolico e quindi stratificati per i fattori di rischio CV, ai fini di programmare la sorveglianza cardiologica e ridurre i danni potenziali dell’ADT.
APA, Harvard, Vancouver, ISO, and other styles
3

Severino, R., V. Ramundo, L. Vuolo, C. Di Somma, G. Lombardi, A. Colao, S. Spiezia, and A. Faggiano. "Tumore bruno della Mandibola in un Paziente con Iperparatiroidismo Primitivo." Giornale di Clinica Nefrologica e Dialisi 22, no. 2 (January 24, 2018): 16–19. http://dx.doi.org/10.33393/gcnd.2010.1206.

Full text
Abstract:
Gli Autori riportano un caso clinico in cui la diagnosi di tumore bruno dell'osso mascellare ha condotto alla definizione del processo patologico primitivo causato da un iperparatiroidismo sostenuto da adenoma primitivo della paratiroide. Il paziente, portatore di insufficienza renale cronica e nefrolitiasi ha eseguito biopsia e TC del mascellare, con diagnosi di tumore bruno associato ad altre aree di osteolisi a carico dell'osso mandibolare. Il profilo ematochimico ha rivelato una ipercalcemia con ipofosforemia associata a aumento del dosaggio sierico del paratormone, pertanto è stata eseguita una scintigrafia delle paratiroidi che ha mostrato la presenza di tessuto iperfunzionante in corrispondenza del terzo inferiore del lobo sinistro della tiroide. Il quadro eco-color-Doppler, ha confermato la presenza di un adenoma paratiroideo di 4,5 cm alla base del lobo sinistro della tiroide. Il paziente è stato sottoposto a terapia con cinacalcet in attesa dell'intervento chirurgico.
APA, Harvard, Vancouver, ISO, and other styles
4

Pini, Giovannalberto, Domenico Veneziano, Vincenzo Altieri, Antonino Inferrera, Paolo Fornara, and Francesco Greco. "Nefrectomia Radicale Laparoendoscopic Single-site (LESS) nel Tumore Renale: Tecnica e Risultati Chirurgici Cosmetici e Valutazione del Dolore Postoperatorio." Urologia Journal 80, no. 22_suppl (April 2013): 16–23. http://dx.doi.org/10.5301/urologia.50000051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Orellana, Fernanda Monteiro, Pablo Leonardo Traete, Victor Notari de Campos, Alan Rechamberg Ziroldo, and Luis Gustavo Morato de Toledo. "Clear - cell renal carcinoma: review of literature in pediatric population / Carcinoma renal de células-claras: revisão bibliográfica na população pediátrica." Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo 65, no. 1 (August 19, 2020): 1. http://dx.doi.org/10.26432/1809-3019.2020.65.017.

Full text
Abstract:
ABSTRACT:Introduction: The first reports of renal tumors originated from the renal tubule epithelium date from 1855, Robin, and 1867, Waldeyer. However, at the same era, some pathologists wrong believed these tumors were originated from adrenal gland tissues due to the fat content of the tumor (hypernephroid tumor theory - origin above the kidney, 1894). The first diagnostic test for renal tumor was excretory urography. Over the years, with the emergence of ultrasonography (US), it has been replaced. Nowadays, after the US screening, all renal lesions should be evaluated, in a complementary way, with computed tomography (CT) - gold standard - in the pre-contrast, arterial, portal, nephrographic phases. This is necessary to characterize the presence of enhancement after contrast. A kidney injury that enhances more than 15 Housfield units (UH) is suspected of kidney cell cancer. There are different subtypes of renal tumors derived from various sites of the nephron. Clear cell Renal Cell Carcinoma (RCC) is one of the subtypes that originates from the renal cortex. It is a rare tumor in children. Objective: The aim of this chapter is to review de incidence, pathology, diagnosis and treatment in clear-cell renal carcinoma in pediatric population. Methods: The authors performed a literary review about clear-cell renal carcinoma in pediatric population using Pubmed Database and Campbell-Walsh Urology as source search.Keywords: Renal cell carcinoma, Tumor, Pediatrics, Kidney, Nefrectomy ResumoRESUMO:Introdução: Os primeiros relatos de tumores renais originados do epitélio do túbulo renal datam de 1855, Robin, e 1867, Waldeyer. Contudo, na mesma época, alguns patologistas acreditavam erroneamente que esses tumores provinham dos tecidos das glândulas supra-renais, devido ao teor de gordura do tumor (hypernephroid tumor theory – origem acima do rim, 1894). O primeiro teste diagnóstico para tumor renal foi a urografia excretora. Ao longo dos anos, com o surgimento da ultrassonografia, esse teste foi substituído. Atualmente, após a leitura da ultrassonografia, todas as lesões renais devem ser avaliadas, de forma complementar, com tomografia computadorizada (TC) – padrão ouro – nas fases pré-contraste, arterial, porta e nefrográfica. Isso é necessário para caracterizar a presença de melhora após contraste. Uma lesão renal que aumenta mais de 15 unidades Housfield (UH) é suspeita de câncer de células renais. Existem diferentes subtipos de tumores derivados de vários locais do néfron. O carcinoma de células renais de células claras (CCR) é um dos subtipos originários do córtex renal. É um tumor raro em crianças. Objetivo: O objetivo deste capítulo é revisar a incidência, a patologia, o diagnóstico e o tratamento do CCR na população pediátrica. Método: Os autores realizaram uma revisão literária sobre carcinoma renal de células claras em população pediátrica usando a base de dados PubMed e o livro Campbell-Walsh de Urologia como fonte de pesquisa.Palavras chave: Carcinoma de células renais, Tumor, Pediatria, Rim, Nefrectomia
APA, Harvard, Vancouver, ISO, and other styles
6

Cruz, Antonio Cesar, Guilherme Lima, Isabella Pinheiro Litvin, and Paulo Eugênio M. A. Costa. "Nefrectomia parcial laparoscópica para tumor T2b em paciente com rim único: relato de caso." Anais da Faculdade de Medicina de Olinda 1, no. 3 (June 1, 2019): 42–44. http://dx.doi.org/10.56102/afmo.2019.68.

Full text
Abstract:
Introdução: Para tumores T2, a maioria dos autores sugere a nefrectomia radical, porém, a literatura carece de relatos de nefrectomia para tumores T2b em pacientes com rim único. Relato de caso: RJAL, sexo masculino, 32 anos com tumor em rim esquerdo medindo 12 cm e agenesia renal direita. No pré-operatório apresentava função renal normal. Foi submetido à nefrectomia parcial laparoscópica em junho de 2016. Evoluiu com elevação da creatinina sérica e anúria, sendo então iniciada terapia renal substitutiva com hemodiálise. Após 20 dias, por apresentar normalização da função renal, optouse por suspender a mesma. O anatomopatológico revelou tratar-se de carcinoma de células renais. No momento, o paciente encontra-se fora de hemodiálise e com TC mostrando rim sem evidências de recidiva tumoral. Comentários: A nefrectomia parcial laparoscópica para tumores renais estádio T2b, é factível e pode ser indicada em casos selecionados como agenesia renal, com resultado oncológico eficaz e manutenção da função renal.
APA, Harvard, Vancouver, ISO, and other styles
7

Delgado, Natalia, Jorge Forero, Rodolfo Varela, and Marino Cabrera F. "Radioablación por laparoscopia de masas renales pequeñas en pacientes octogenarios: técnica paso a paso." Revista Urología Colombiana / Colombian Urology Journal 27, no. 03 (May 29, 2018): 290–93. http://dx.doi.org/10.1055/s-0038-1656518.

Full text
Abstract:
Introducción La cirugía preservadora de nefronas sigue siendo el gold standard de manejo en pacientes con tumores renales pequeños. La ablación por radiofrecuencia es una alternativa mínimamente invasiva con evidencia sustancial en efectividad en la erradicación tumoral completa. Objetivo Reportar el caso y la técnica paso a paso de la radioablación laparoscópica de un tumor renal en un centro de oncología de III nivel de Bogotá - Colombia. Materiales y Métodos Revisión de la historia clínica de un paciente con hallazgo incidental de una masa renal pequeña sometido a radioablación laparoscópica en un centro de oncología de III nivel de Bogotá. Conclusión La ablación por radiofrecuencia es una alternativa válida para el tratamiento de tumores renales pequeños, especialmente en adultos mayores y con alto riesgo quirúrgico, ofreciendo tasas de supervivencia libre de enfermedad comparables con la nefrectomía parcial.
APA, Harvard, Vancouver, ISO, and other styles
8

Andino Guillén, Juan Pablo, and Leonardo Rayo Meza. "Tumores Renales Bilaterales: Reporte de caso." Revista Guatemalteca de Urología 9, no. 2 (February 23, 2022): 1–5. http://dx.doi.org/10.54212/27068048.v9i2.2.

Full text
Abstract:
Objetivo: Reportar un caso de tumores renales bilaterales < 10 cm, limitado a las unidades renales sin datos de metástasis, revisando antecedentes y abordaje médico-quirúrgico. Presentación de Caso Clínico: Paciente masculino de 41 años de edad, sin comorbilidades presentes, con antecedentes de cirugía de tumor cerebral en fosa posterior en 2019. Acude con dolor lumbar de predominio derecho, al examen físico no se palpan masas. UroTC evidencia presencia de tumores renales bilaterales, masa derecha de 47 x 60 x 46 mm, masa izquierda de 51 x 68 x 59 mm, con realce al medio de contraste. Se realizo nefrectomía polar bilateral, con resultado histopatológico de carcinoma de células renales claras bilateral. Discusión: El abordaje de los tumores renales bilaterales es complejo, cuando las características por imagen sugieren un alto grado de malignidad se deberá realizar un abordaje hacia la resección del tumor en sus modalidades Nefrectomía Radical (NR) o nefrectomía parcial (NP). La evidencia es débil en cuanto al adecuado abordaje cuando las masas son bilaterales, debido a que solo se disponen revisiones de casos limitados en la literatura mundial. El riesgo en el transquirúrgico es elevado por las complicaciones que se pueden presentar con una alta presentación de sangrado que no se pueda controlar. En general la NP se considera únicamente en tumores > 4cm que se encuentren limitados a la unidad renal en condiciones especiales como pacientes monorrenos, tumores renales bilaterales o ERC en estadios avanzados.1 Conclusión: La cirugía conservadora de nefronas es un recurso útil, con buenos resultados quirúrgicos en pacientes con condiciones especiales, a pesar de encontrar hallazgos histopatológicos desfavorables con márgenes tomados la evidencia nos indica que no se incrementa el riesgo de metástasis o disminución del carcinoma de células claras, solo un 16% de los casos con márgenes quirúrgicos positivos tienen recurrencia local del tumor.2,3
APA, Harvard, Vancouver, ISO, and other styles
9

Vasquez-Sullca, Roy R., Alfredo D. Balcazar-Reyes, Herman Yalta-Arce, and Luis A. Allemant-Mori. "Carcinoma renal con cuadro clínico de infección urinaria recurrente en paciente joven." Anales de la Facultad de Medicina 80, no. 1 (March 27, 2019): 60–63. http://dx.doi.org/10.15381/anales.v80i1.15427.

Full text
Abstract:
El cáncer renal es una neoplasia con una tasa de incidencia de 4,4% por 100 000 habitantes a nivel mundial; el carcinoma de células renales representa el 90% de los tumores renales malignos. Las infecciones urinarias recurrentes tienen una prevalencia del 19% y constituyen infecciones de al menos dos episodios en seis meses, o al menos tres episodios en un año. Presentamos el caso de una paciente mujer de 25 años que presentó cuadros de infecciones urinarias recurrentes y que en un estudio tomográfico se evidenció una tumoración renal izquierda. Se le realizó nefrectomía radical cuya pieza operatoria confirmó diagnóstico patológico de carcinoma renal de células clara. En pacientes jóvenes el carcinoma renal es una tumoración aún más rara, que representa 8,7% del total de pacientes diagnosticados de cáncer renal. Se debe promover en la consulta médica la sospecha clínica a mujeres jóvenes con infecciones urinarias recurrentes solicitando exámenes de imagen, con la finalidad de garantizar un temprano diagnóstico y tratamiento adecuado si se tratara de un tumor renal.
APA, Harvard, Vancouver, ISO, and other styles
10

Tillyashaykhov, Mirzagaleb, Elena Boyko, and Shakhnoza Jumaniyazova. "EXTRATUMOR MICROENVIRONMENT IN RENAL CELL CARCINOMA." UZBEK MEDICAL JOURNAL 2, no. 4 (April 30, 2021): 5–12. http://dx.doi.org/10.26739/2181-0664-2021-4-1.

Full text
Abstract:
The review is focused on studying the immunosuppressive mechanisms acting in the microenvironment of renal cell carcinoma tumors. The report contains a collection of basic literature materials on the study of tumor growth factors that boost tumor cell proliferation and metastasis. The tumor microenvironment (TME) limits the immune surveillance of tumor-associated antigens and the effectiveness of immune checkpoint inhibitors. Although renal cell carcinoma is one of several tumor types sensitive to immune checkpoint inhibitors, the efficacy of these agents is likely to be limited by different tumor-infiltrating myeloid cells of bone marrow that make up the TME. Several strategies aimed at eliminating the onset of these cells in tumor tissue or neutralizing their immunosuppressive function have shown encouraging results in animal tumor models and clinical trials.Keywords: cytotoxic T lymphocytes (CTL), immune checkpoint inhibitor (ICI), tumor microenvironment (MEV), myeloid-derived suppressor cells (MDSC), regulatory T cells (Tregs), renal cell carcinoma (RCC), tumor-associated macrophages (TAM), vascular endothelial growth factor (VEGF)
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Tumore renale"

1

STELLA, MARTINA. "Identification of molecular alterations associated with the progression of clear cell Renal Cell Carcinoma by mass spectrometric approaches." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2019. http://hdl.handle.net/10281/241159.

Full text
Abstract:
Il carcinoma a cellule renali rappresenta la più frequente forma di tumore al rene, e il carcinoma a cellule chiare ne è il morfotipo più ricorrente (80% dei casi). Ad oggi la nefrectomia, totale o parziale, rimane il trattamento di elezione. E’ evidente, quindi, la necessità di indagare a fondo gli aspetti molecolari associati alla progressione del tumore, con il fine ultimo di produrre conoscenze utili alla diagnosi o trattamento delle lesioni stesse. In questo lavoro abbiamo utilizzato approcci proteomici complementari per lo studio dei processi associati all’insorgenza e alla progressione (stadio e grado) dei tumori: Matrix-Assisted Laser Desorption/Ionisation – Mass Spectrometry Imaging (MALDI-MSI) e nLC-ESI MS/MS. Combinando l’utilizzo di fluidi biologici, che non richiedono tecniche invasive, e l’analisi diretta del tessuto tumorale, abbiamo approfondito lo studio delle modifiche proteomiche associate alla progressione del carcinoma renale a cellule chiare. Inizialmente abbiamo considerato le informazioni ottenibili da diversi fluidi biologici: urine e plasma. Abbiamo quindi valutato la distribuzione spaziale di peptidi triptici in aree del tumore a diversi gradi (MALDI-MSI), associandovi l’analisi di omogenati di tessuto per aumentare le informazioni quali-quantitative ottenibili (nLC-ESI MS/MS). Infine, abbiamo mostrato come informazioni relative alla dimensione e allo stadio della lesione siano rilevabili anche dalle urine del paziente. Attualmente sono in corso studi più approfonditi sui processi biologici coinvolti e dati preliminari suggeriscono un ruolo fondamentale dei processi metabolici nella progressione del tumore. Inoltre, è stato messo a punto un protocollo per l’analisi di N-glicani direttamente da tessuto, che sarà utilizzato per valutare la loro espressione in diverse aree del tumore. In conclusione, siamo fiduciosi che tutti i dati raccolti possano portare a una miglior comprensione dei processi coinvolti nella progressione del tumore renale a cellule chiare.
Renal Cell Carcinoma (RCC) is the most frequent form of kidney cancer and approximately 80% of cases are defined as clear cell RCC (ccRCC). Partial or total nephrectomy remain the gold standard for the routine treatment of ccRCC, therefore a better understanding of molecular aspects associated to tumour progression could be useful for its diagnosis, prognosis and treatment. Nowadays proteomic approaches are more readily used to investigate the processes that drive disease onset and progression. In this work, two complementary technologies, Matrix-Assisted Laser Desorption/Ionisation – Mass Spectrometry Imaging (MALDI-MSI) and nLC-ESI MS/MS, were used to detect alterations within tumour lesions and to perform protein identification and quantification. Likewise, employing both tissue and body fluids (urine-plasma) ensures a strong correlation with the disease, a high degree of lesion specificity whilst at the same time enables the use of more readily accessible samples. Therefore, the aim of this study was to investigate proteomic changes in different human specimens related to early pathological modifications and ccRCC progression. Our study on ccRCC started with the evaluation of the information that can be obtained from urine and plasma from patients with ccRCC. Then, MALDI-MSI was used to evaluate the spatial distribution of tryptic peptides directly on tissue, and the molecular data has been correlated to morphological annotation (grade). Moreover, in situ findings has been combined with those obtained from tissue homogenates and better understanding of molecular changes among the four grades has been provided. Finally, we demonstrate the possibility to detect in urine alterations determined by the stage of the lesion. Further work related to the study of ccRCC tissue is currently ongoing. At first, the biological role of the proteins resulted to be altered and the pathways involved in grade progression are under investigation. Preliminary data suggest the essential role of metabolic alterations in ccRCC progression. Moreover, a protocol for realised N-glycans analysis directly on tissue has been optimised and this protocol will be used to evaluate N-glycans trait on different ccRCC grade areas. In conclusion, it is hoped that the data obtained along with the additional work planned, could better clarify the biological processes involved in ccRCC progression.
APA, Harvard, Vancouver, ISO, and other styles
2

SQUEO, VALERIA. "Alterazioni del peptidoma serico di pazienti con tumore renale valutate tramite "label-free" (nLC-ESI-MS/MS) e "peptide profiling" (MALDI-MS/MS)." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2013. http://hdl.handle.net/10281/43783.

Full text
Abstract:
Il progetto di questa ricerca è stato rivolto allo studio e alla caratterizzazione del peptidoma serico di soggetti sani e pazienti con carcinoma renale, così come alla diagnosi differenziale delle forme di tumore renale maligno da lesioni benigne. A questo proposito sono stati purificati, mediante tecnica ClinProt che utilizza microparticelle magnetiche funzionalizzate, il siero di un ampio numero di pazienti affetti da ccRCC e soggetti controllo, estendendo lo studio anche a pazienti affetti da non-ccRCC. Le analisi di profiling peptidico sono state condotte mediante SM MALDI-TOF seguita da elaborazione dei profili spettrali per all’individuazione di clusters con potenziale diagnostico. Inoltre si è cercato di identificare proteine/peptidi con alterata espressione serica. A questo scopo sono state effettuate analisi mediante tecnologia nLC-ESI MS/MS e MALDI-TOF MS/MS. I risultati del "profiling" tramite MALDI-TOF sono stati verificati utilizzando un approccio proteomico diverso basato su una quantificazione relativa label-free in nLC-ESI MS/MS.
APA, Harvard, Vancouver, ISO, and other styles
3

Pedro, Renato Nardi. "Uso da nanopartícula de ouro ligada a moléculas de fator alfa de necrose tumoral como adjuvante da termoablação por radiofrequência de tumores renais = modelo animal experimental." [s.n.], 2010. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310676.

Full text
Abstract:
Orientadores: Marcelo Lopes de Lima, Nelson Rodrigues Netto Junior
Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-17T00:02:35Z (GMT). No. of bitstreams: 1 Pedro_RenatoNardi_D.pdf: 3805668 bytes, checksum: 8b1ea901163cf75ede5f727e7f455e0c (MD5) Previous issue date: 2010
Resumo: O tratamento definitivo das massas renais malignas é primordialmente cirúrgico, sendo a nefrectomia radical eleita por muitos anos a cirurgia padrão para o tratamento do câncer renal localizado. Entretanto, com o envelhecimento populacional, maiores são as preocupações em se manter a capacidade funcional dos órgãos e sistemas do corpo humano. Portanto, a necessidade de se preservar tecido renal sadio durante o tratamento do câncer renal localizado, com auxílio de cirurgias parciais poupadoras de néfrons, se tornou imperativa. O tratamento de lesões renais sólidas pequenas passou a ter diferentes formas de abordagem, que variam desde técnicas de termoablação percutânea ou laparoscópica, nefrectomia parcial laparoscópica e aberta à até tradicional nefrectomia radical aberta. O uso de modalidades de tratamento cirúrgico com mínimo grau de agressão passou a ganhar atenção, devido à rápida recuperação do paciente, ao menor risco de complicações cirúrgicas e aos bons resultados oncológicos. Ablação por radiofreqüência (ARF) tem se mostrado um meio eficiente no tratamento de tumores renais pequenos e exofiticos. Atualmente, sua indicação é restrita a lesões de até 4 cm. O presente estudo foi montado para avaliar o uso conjunto da nanopartícula de ouro e fator alfa de necrose tumoral (TNF alfa) à ARF no tratamento de um modelo experimental de tumor renal. Materiais e Métodos: Trinta e sete coelhos brancos da raça New Zealand tiveram implantados em seus rins, através de uma laparotomia, um fragmento de 1 mm3 de tumor VX-2. Após 14 dias do implante, quando seus rins haviam desenvolvido uma lesão tumoral sólida menor que 1 cm, os animais foram divididos em 3 grupos de 10 e 1 grupo de 7 integrantes (sham) de acordo com o tratamento selecionado para o tumor renal focal: 1) Nanopartícula com TNF alfa; 2) Ablação por radiofreqüência; 3) Nanopartícula com TNF alfa seguido de Ablação por radiofreqüência; 4) Grupo sham. Todos os animais foram submetidos a mesma cronologia de tratamento, composta por 2 laparotomias e eutanásia. Os grupos tratados com as nanopartículas de ouro com fator alfa de necrose tumoral isolada ou complementarmente, as receberam 4 horas antes do procedimento cirúrgico na dose de 200 µm/Kg. A análise de resultados foi realizada com medidas macroscópicas e microscópicas do volume da área de ablação ou tumoral, segundo a fórmula do volume de uma elipsóide. Avaliação estatística foi realizada com Teste T Student, sendo considerado significante p<0.05. Resultados: O grupo que recebeu a nanopartícula com fator alfa de necrose tumoral e depois foi submetido à ARF apresentou maior zona de morte celular completa quando comparado ao grupo tratado somente com ablação por radiofreqüência (0.30 ± 0.07 vs 0.23 ± 0.03 mL, P=.03). A zona de transição foi menor no grupo que recebeu a nanopartícula com fator alfa de necrose tumoral e ablação por radiofreqüência quando comparada ao grupo tratado somente com ablação por radiofreqüência (0.08 ± 0.02 vs 0.13 ± 0.05 mL, P =.01). Conclusão: O presente estudo demonstrou que o uso da nanopartícula de ouro com TNF alfa sensibiliza o insulto térmico sofrido por tumores sólidos decorrentes da ablação por radiofreqüência
Abstract: Radical nephrectomy has long been considered as gold standard treatment for localized renal tumors. However due to an increase in life expectation, organ sparing surgeries have emerged with the purpose of preserving as much healthy tissue as possible. Therefore, nephron sparing surgeries have become another valid option for localized renal tumors. There are different modalities of nephron sparing procedures, including open partial nephrectomy, laparoscopic nephrectomy and termoablative procedures. The later is associated with less morbidity and fast patient recovery. Radiofrequency ablation (RFA) is a well-known termoablative procedure and it has been most effective when the tumors are small, exophytic, and away from vital structures. The present study was designed to analyze the adjuvant use of gold nanoparticle with tumor necrosis factor alpha prior to radiofrequency ablation in a translational model of localized renal tumor. Material and Methods: A total of 37 New Zealand White rabbits had VX-2 tumors implanted into their kidneys; they were allowed to grow for 14 days, when a tumor mass of less than 1 cm could be detected. The animals were then split into 3 treatment groups of 10 rabbits each and a sham group of 7 rabbits as follows: (1) Tumor necrosis factor alpha plus nanoparticle, (2) Radiofrequency ablation, (3) Tumor necrosis factor alpha nanoparticle (200 µm/Kg) followed 4 hours later by radiofrequency ablation. All groups were subjected to the same milestones of the experiment which was comprised of 2 laparotomies and sacrification. Gross and microscopic measurements of the ablation size as well as histological analysis using hematoxylin and eosin staining were performed to determine the effect of TNF alpha nanoparticle on the ablation. Statistical analysis was performed with Student's T test, considering p < 0.05 as significant. Results: The RFA plus TNF alpha nanoparticle group had a larger zone of complete cell death than the RFA-only group (0.30 ± 0.07 vs 0.23 ± 0.03 mL, P=.03). The zone of partially ablated tissue was smaller in the RFA plus TNF alpha nanoparticle group than in the RFA-only group (0.08 ± 0.02 vs 0.13 ± 0.05 mL, P =.01). Conclusions: We have demonstrated the efficacy of TNF alpha nanoparticle in enhancing RFA in a translational kidney tumor model. The potential usage of TNF alpha nanoparticle to improve RFA of renal cell carcinoma merits further study
Doutorado
Fisiopatologia Cirúrgica
Doutor em Ciências
APA, Harvard, Vancouver, ISO, and other styles
4

Andersson, Charlotta. "Significance of Wilms’ tumor gene 1 as a biomarker in acute leukemia and solid tumors." Doctoral thesis, Umeå universitet, Institutionen för medicinsk biovetenskap, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-120912.

Full text
Abstract:
Wilms’ tumor gene 1 (WT1) is a zinc finger transcriptional regulator with crucial functions in embryonic development. Originally WT1 was described as a tumor suppressor gene, but later studies have shown oncogenic properties of WT1 in a variety of tumors. Because of its dual functions in tumorigenesis, WT1 has been described as a chameleon gene. In this thesis, the significance of WT1 as a biomarker was investigated in acute myeloid leukemia (AML), clear cell renal cell carcinoma (ccRCC), ovarian carcinoma (OC) and childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Previous studies have suggested that expression of WT1 is a potential marker for detection of minimal residual disease (MRD) in AML. We aimed to define expression of WT1 as an MRD marker in AML. In adult AML patients, we found that a reduction of WT1 expression in bone marrow (≥ 1-log) detected less than 1 month after diagnosis was associated with an improved overall survival (OS) and freedom from relapse (FFR). In peripheral blood, a reduction of WT1 expression (≥ 2-log) detected between 1 and 6 months after treatment initiation was associated with an improved OS and FFR. WT1 harbor pathogenic genetic variants in a considerable proportion of AML and T-lymphoblastic leukemia (T-ALL), but mutations have not been reported in BCP-ALL. We aimed to evaluate the clinical impact of WT1 mutations and single nucleotide polymorphisms (SNPs) in BCP-ALL. Pathogenic mutations in the WT1 gene were rarely seen in childhood BCP-ALL. However, five WT1 SNPs were identified. In survival analyses, WT1 SNP rs1799925 was found to be associated with worse OS, indicating that WT1 SNP rs1799925 may be a useful marker for clinical outcome in childhood BCP-ALL. We also explored whether WT1 mutations and SNPs in ccRCC could be used as biomarkers for risk and treatment stratification. We therefore examined whether SNPs or mutations in WT1 were associated with WT1 expression and clinical outcome. Sequencing analysis revealed that none of the previously reported WT1 mutations were found in ccRCC; however, we identified six different WT1 SNPs. Our data suggest that pathogenic WT1 mutations are not involved in ccRCC, and the prognostic significance of WT1 SNPs in ccRCC is considerably weak. However, a favorable OS and disease-specific survival were found in the few cases harboring the homozygous minor allele. OC has a poor prognosis, and early effective screening markers are lacking. Serous OCs are known to express the WT1 protein. Overexpressed oncogenic proteins can be considered potential candidate antigens for cancer vaccines and T-cell therapy. It was therefore of great interest to investigate whether anti-WT1 IgG antibody (Ab) measurements in plasma could serve as biomarkers of anti-OC response. We found limited prognostic impact, but the results indicated that anti-WT1 IgG Ab measurements in plasma and WT1 staining in tissue specimens could be potential biomarkers for patient outcome in the high-risk subtypes of OCs. In conclusion, the results of this thesis indicate that WT1 gene expression can provide information about MRD of patients with AML, and WT1 SNP rs1799925 may be used as a biomarker for predicting clinical outcome in childhood BCP-ALL. In ccRCC, the prognostic significance of WT1 SNPs is weak and limited to the subgroup of patients that are homozygous for the minor allele. In OCs anti-WT1 IgG Ab measurement in plasma and WT1 staining in tissue specimens could possibly be used as biomarkers for predicting patient outcome in the high-risk subtypes of OCs.
APA, Harvard, Vancouver, ISO, and other styles
5

Patrício, Patrícia Carvalho. "Analysis of PAX2 gene alterations in renal cell tumors." Master's thesis, Faculdade de Ciências e Tecnologia, 2010. http://hdl.handle.net/10362/10574.

Full text
Abstract:
Dissertation for applying to a Master’s Degree in Molecular Genetics and Biomedicine submitted to the Sciences and Technology Faculty of New University of Lisbon
Background: Renal cell tumors (RCT) represent a heterogeneous group of malignancies arising from the epithelium of the renal tubules. PAX2 (Paired-box 2) is a transcription factor belonging to the evolutionarily conserved paired-box family that is required during development of the central nervous system and genitourinary tract. PAX2, which is considered a proto-oncogene, is normally suppressed at the later stages of embryonic development and reactivated during the carcinogenic process in some cancer models. Previously published data indicate that significant expression of PAX2 protein occurs in three of the most prevalent renal cell tumor subtypes - clear cell RCC (ccRCC), papillary RCC (pRCC) and oncocytoma - but not in chromophobe RCC (chrRCC). Moreover, it has been reported that PAX2 expression could be repressed by aberrant methylation at the end of nephrogenesis. Finally, FISH and cytogenetic analysis, demonstrated loss of chromosome 10 (to which PAX2 is mapped) in 40 to 60% of chrRCC cases. Aims: The main goal of this study was to identify epigenetic and/or genetic alterations affecting the PAX2 gene in a series of renal cell tumors, representing the four major subtypes. Specifically, our aims were to: (1) analyze the expression of PAX2 in different renal cell tumor subtypes, both at mRNA and at protein level; (2) determine whether the regulation of PAX2 expression occurs by epigenetic mechanisms, by assessing its promoter methylation status; (3) analyze the association between PAX2 copy number and gene expression; (4) evaluate the potential use of PAX2 epigenetic/genetic alterations as a biomarker for discrimination between chrRCC and oncocytoma. Methodology: In this study, 120 samples of renal cell tumors (30 of each subtype: ccRCC, pRCC, chrRCC, and oncocytoma) and 4 normal kidney tissues were tested. First, PAX2 protein expression was assessed by immunohistochemistry and the PAX2 mRNA expression levels were determined by quantitative reverse transcription PCR (qRT-PCR), using HPRT1 as an endogenous control. The methylation status of PAX2 promoter was assessed by methylation-specific PCR using two different sets of primers that annealed to adjacent regions in the promoter. The relationship between the number of PAX2 copies and its expression in chrRCC was analyzed by FISH. The chi-square test or Fisher’s exact test were used to seek for differences in the frequency of immunoreactivity for PAX2 protein among the four RCT subtypes....
CI-IPOP-4 and the Calouste Gulbenkian Foundation (Project # 96474)
APA, Harvard, Vancouver, ISO, and other styles
6

Dijkhuizen, Trijntje. "Genetic contributions to the classification of renal cell cancer." [S.l. : [Groningen] : s.n.] ; [University Library Groningen] [Host], 1997. http://irs.ub.rug.nl/ppn/159282535.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hudon, Valerie. "Investigating tumor suppressor genes involved in renal cell carcinomas." Thesis, McGill University, 2010. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=86607.

Full text
Abstract:
Kidney cancer is a complex disease comprising several types of renal carcinomas, which are classified in different subtypes based on their histological characteristics. A small number of cases of renal cancers are due to hereditary predispositions and nearly all the knowledge on the molecular pathogenesis of kidney cancers was learned by the investigation of these hereditary forms of renal carcinomas. In this thesis, we studied two hereditary diseases predisposing to the development of kidney cancer, von Hippel Lindau (VHL) and Birt-Hogg-Dubé (BHD) syndromes, and their causative genes, VHL and FLCN respectively. First, we investigated the role of the extracellular matrix (ECM) regulation by VHL during tumorigenesis and angiogenesis, and we demonstrated that inactivation of the VHL-ECM assembly pathway results in highly vascularized tumors with a disrupted ECM. We concluded that loss of the ECM assembly promotes and maintains tumor angiogenesis by providing a way for new blood vessels to invade the tumor tissue. In the second part of this thesis, we developed a novel VHL mouse model to investigate the possible cooperation between VHL and p53 during tumorigenesis. We observed that inactivation of both tumor suppressor genes accelerate the formation of liver hemangiomas and splenic hemangiosarcomas. Furthermore, concomitant deletion of VHL and p53 abolished the development of lymphoma usually associated with loss of p53. Our results indicate that the phenotypes arising following the inactivation of VHL and p53 is organ-dependent. Finally, to study the pathogenesis of the BHD syndrome, we developed a new mouse model using an established embryonic stem cell line. We described the murine Flcn expression pattern and noticed that homozygous disruption of Flcn was embryonically lethal early during development. Furthermore, we observed a continuum of kidney lesions from renal tubules hyperproliferation to rare adenoma. FLCN tumor suppressor role was also substantiated usi
Le cancer du rein est une maladie complexe qui comprend différents types de cancers classifiés selon leurs caractéristiques histologiques. Certains cas de cancers rénaux sont attribuables à une prédisposition héréditaire et l'étude de ces formes héréditaires de cancer a largement contribué au développement des connaissances concernant la pathogenèse des cancers rénaux. Le travail décrit dans cette thèse porte sur deux maladies héréditaires prédisposant au développement de tumeurs rénales soit la maladie de Von Hippel-Lindau (VHL) et le syndrome de Birt-Hogg-Dubé (BHD) ainsi que les gènes associés à ces dernières, VHL et FLCN respectivement. Premièrement, nous avons étudié le rôle de la régulation de l'assemblage de la matrice extracellulaire (MEC) par VHL durant la tumorigénèse et nous avons démontré que l'assemblage inadéquat de la MEC corrèle avec une croissance tumorale accrue et induit la formation de tumeurs fort vascularisées. Nous avons conclu que la perte de l'intégrité de la MEC favorise l'angiogénèse tumorale en fournissant une voie permettant aux vaisseaux sanguins d'infiltrer la tumeur. Deuxièmement, nous avons développé un modèle murin pour étudier la coopération potentielle entre VHL et p53 durant le développement tumoral. Nous avons observé que l'inactivation simultanée de VHL et p53 accélère la progression d'hémangiomes du foie et d'hémangiosarcomes de la rate. De plus, la perte concomitante de VHL et p53 inhibe le développement de lymphomes normalement associés à l'inactivation de p53. Nos résultats indiquent que les phénotypes apparaissant suite à l'inactivation de VHL et p53 varient selon l'organe étudié. Finalement, nous avons développé un modèle murin pour étudier de la pathologie associée au syndrome BHD et à avons observé la formation d'un continuum de lésions rénales allant de l'hyperprolifération des tubules rénaux à de rares adénomes. Finalement, nous avons conf
APA, Harvard, Vancouver, ISO, and other styles
8

Anderson, Jane Ann. "Autotaxin expression in bladder and renal cancer." Thesis, University of Birmingham, 2016. http://etheses.bham.ac.uk//id/eprint/6946/.

Full text
Abstract:
Autotaxin is an extracellular enzyme that generates lysophosphatidic acid (LPA). LPA binds up to six different cell surface G protein-coupled receptors to initiate signaling resulting in cell survival, invasion and angiogenesis. For this reason autotaxin has emerged as a therapeutic target in several different malignancies. I have used immunohistochemistry to explore the expression of autotaxin and its correlation with clinico-pathological variables in bladder and renal cancer. I show that in bladder cancer, tumours from patients with muscle invasive disease were significantly more likely to show strong autotaxin expression than were those tumours from patients without evidence of muscle involvement (p=0.009). This observation is not only consistent with the known functions of autotaxin/LPA in promoting tumour invasion, but suggests that the potential use autotaxin inhibitors in preventing bladder cancer progression warrants further investigation. Although I failed to detect autotaxin expression in the tumour cells of patients with renal cancer, I did observe high-level expression of autotaxin on the tumour-associated vasculature, which in many cases was not apparent in blood vessels of matched normal renal tissues. This points to an important role for autotaxin in renal cancer-associated angiogenesis and suggests a potential role for autotaxin inhibition as an anti-angiogenesis therapy.
APA, Harvard, Vancouver, ISO, and other styles
9

Faust, Bethany, Candelaria MD Deimundo-Roura, Cara E. MD-PhD Marin, and Marcela MD Popescu. "Cystic Nephroma in a Child with DICER1 Mutations." Digital Commons @ East Tennessee State University, 2021. https://dc.etsu.edu/asrf/2021/presentations/48.

Full text
Abstract:
Cystic nephromas are rare, multiloculated cysts on the kidneys that occur mostly in early childhood. They are considered to be on the same spectrum as cystic partially differentiated nephroblastomas (CPDN) and Wilm’s tumors (WT). They are mostly benign, however, when cystic nephroma is associated with DICER1 mutation, the patient is predisposed to other, more aggressive tumors. DICER1 mutations are not seen in CPDN or WT, so molecular evaluation can help differentiate between them if the histology is unclear. The DICER1 gene is on chromosome 14 and it functions to make microRNA that attaches to mRNA and represses protein synthesis. Mutations of this gene predispose patients to neoplasms on various organs such as the lung, kidneys, ovaries, and thyroid. The data in this case report was gathered via direct patient care and patient chart review. An 18-month-old previously healthy female was hospitalized for a newly diagnosed abdominal mass found on palpation during a well child evaluation. The ultrasound revealed a 9 cm cystic mass on the left kidney and the patient was subsequently sent to St. Jude Children’s Research Hospital. Further evaluation via CT scan has shown a large left renal mass that invaded the ureter and bladder, as well as enlarged lymph nodes in the left suprarenal space and a single 3mm right pulmonary nodule. At this time, cystic Wilm’s tumor was considered and the patient underwent a left radical ureteronephrectomy with lymph node sampling. Cytology report of the pelvic fluid had some inflammatory cells, but no tumor cells were seen in the sample. All of the sampled lymph nodes were also negative for tumor cells. The histological analysis of the mass revealed multiple cystic cavities separated by septa. No blastemal elements (WT1 immunostain was negative) or distinct solid areas were identified, which made the diagnosis of cystic Wilm’s tumor unlikely. The diagnosis of cystic nephroma (CN) vs cystic partially differentiated nephroblastoma (CPDN) is determined histologically by looking at the components of the septa – which, in this case, due to a marked inflammatory infiltrate expending the septa, made the morphology be more congruent with CPDN. Molecular testing of the tumoral tissue identified two DICER1 mutations (DICER1 frameshift mutation and DICER1 D1709E). Patient was subsequently diagnosed with Cystic Nephroma Stage I and further surveillance will be continued to monitor for more neoplasms associated with this mutation. This case highlights a rare disorder that predisposes patients to multiple neoplasms. Histology may not always be sufficient in determining the diagnosis, especially in differentiating CN from CPDN. Molecular evaluation may be helpful for the initial diagnosis and in order to provide adequate genetic counseling. Clinicians should be aware of DICER1 syndrome so they can adequately survey the at-risk patients for a range of benign and malignant neoplasms.
APA, Harvard, Vancouver, ISO, and other styles
10

Slater, Amy Amelia. "Epigenetic and genetic profiles of rare renal cancers." Thesis, University of Birmingham, 2016. http://etheses.bham.ac.uk//id/eprint/6933/.

Full text
Abstract:
The aim of this study was to characterise the genetic and epigenetic profiles of rare forms of sporadic renal cancers (RCC) and identify differential patterns of DNA methylation or somatic mutations that may permit distinction between different subtypes of RCC and could facilitate disease prognosis or identify molecular pathways that could be targeted therapeutically. Illumina Infinium HumanMethylation 450K BeadChip permitted the comparison of the epigenome of the malignant chromophobe RCC and the benign renal oncocytoma. This study identified several genes to be differentially hypermethylated in chromophobe RCC, and renal oncocytoma showing that although both visually and pathologically similar, both tumours have a distinct methylation pattern. Whole exome sequencing (WES) of renal oncocytoma samples identified somatic mutations in eighteen genes involved in a variety of cellular functions. Sanger sequencing was then used to confirm the mutations identified, followed by further screening by Sanger in a cohort of additional renal oncocytoma samples to identify if the somatic mutations are recurrent. Modern high throughput and quantitative techniques have permitted further characterisation of these rare renal cancers and have enabled unique insights into their molecular genetics, findings that may hopefully be of clinical benefit in the future.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Tumore renale"

1

Löhr, Eberhard, and Lutz-Dietrich Leder, eds. Renal and Adrenal Tumors. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71207-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pritchard-Jones, Kathy, and Jeffrey S. Dome, eds. Renal Tumors of Childhood. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-44003-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bukowski, Ronald M., and Andrew C. Novick, eds. Clinical Management of Renal Tumors. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-60327-149-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gorin, Michael A., and Mohamad E. Allaf, eds. Diagnosis and Surgical Management of Renal Tumors. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-92309-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Arie, Belldegrun, ed. Renal and adrenal tumors: Biology and management. New York: Oxford University Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1928-, Löhr E., Leder Lutz-Dietrich, and Ackermann R. 1941-, eds. Renal and adrenal tumors: Pathology, radiology, ultrasonography, magnetic resonance (MRI), therapy, immunology. 2nd ed. Berlin: Springer-Verlag, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schoenfeld, David Aaron. Characterizing the Mechanism of Tumor Suppression by PBRM1 in Clear Cell Renal Cell Carcinoma. [New York, N.Y.?]: [publisher not identified], 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Brouwenstijn, Nathalie. Characterization of the T-cell mediated immune response to renal cell carcinoma. [Leiden: University of Leiden], 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Frances, Flinter, Maher E. R, Saggar-Malik Anand, and Crawfurd M. d'A, eds. The genetics of renal disease. Oxford: Oxford University Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lara, Primo N., and Eric Jonasch. Kidney cancer: Principles and practice. Heidelberg: Springer-Verlag, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Tumore renale"

1

Al-Salem, Ahmed H. "Renal Tumors: Wilms Tumor (Nephroblastoma)." In An Illustrated Guide to Pediatric Surgery, 479–90. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-06665-3_62.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Al-Salem, Ahmed H. "Renal Tumors: Wilms Tumor (Nephroblastoma)." In Atlas of Pediatric Surgery, 617–42. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-29211-9_65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lopez-Beltran, Antonio, Carmen L. Menendez, Rodolfo Montironi, and Liang Cheng. "Renal Tumors and Tumor-Like Conditions." In Rare Tumors and Tumor-like Conditions in Urological Pathology, 1–61. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-10253-5_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tyson, Mark, and Michael Ritchey. "Wilms tumor and other renal tumors." In Pediatric Urology, 323–31. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781118473382.ch33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Weill, Francis S., Edmond Bihr, Paul Rohmer, and François Zeltner. "Renal Tumors." In Renal Sonography, 83–102. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-70417-8_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Paulino, Arnold C. "Wilms’ Tumor and Other Childhood Renal Tumors." In Decision Making in Radiation Oncology, 1089–104. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16333-3_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hamilton, Thomas E., and Robert C. Shamberger. "Renal Tumors." In Pediatric Surgery, 1–39. Berlin, Heidelberg: Springer Berlin Heidelberg, 2020. http://dx.doi.org/10.1007/978-3-642-38482-0_147-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Aganovic, Lejla, and Richard H. Cohan. "Renal Tumors." In IDKD Springer Series, 1–11. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-75019-4_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Estlin, Edward J., and Norbert Graf. "Renal Tumors." In Pediatric Hematology and Oncology, 193–215. Oxford, UK: Wiley-Blackwell, 2010. http://dx.doi.org/10.1002/9781444315134.ch13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Imbach, Paul. "Renal Tumors." In Pediatric Oncology, 133–42. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-06010-1_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Tumore renale"

1

de Brito Oliveira dos Santos, Ellen, Emilly Chagas Barros Martins, Eliza Barroso Siqueira, Adilson Gonçalves Marinho Junior, Maria Júlia Silva Moreira de Souza, and Thaís Louvain de Souza. "Tumor de Wilms: relato de caso." In Semana Científica da Faculdade de Medicina de Campos. Faculdade de Medicina de Campos, 2022. http://dx.doi.org/10.29184/anaisscfmc.v12022p26.

Full text
Abstract:
Introdução: O tumor de Wilms (TW) ou nefroblastoma representa o tumor renal maligno pediátrico mais comum, responsável por 80% de todos os tumores pediátricos renais. Em relação à faixa etária, 95% dos casos correspondem a crianças menores de 10 anos, sendo majoritariamente menores de 5 anos.. A incidência é de 1:10.000 crianças com idade inferior a 15 anos. 3 Apresenta-se uni ou bilateralmente em até 13% dos pacientes. Objetivo: Relatar um caso de tumor de Wilms em uma criança que compareceu à consulta com quadro de constipação intestinal e presença de massa abdominal à direita. Descrição do caso: Paciente do sexo feminino, 4 anos, residente em Campos dos Goytacazes. Ao exame físico: bom estado geral, ritmo cardíaco regular em dois tempos, com bulhas normofonéticas, sem sopros; frequência cardíaca 120 bpm; ausculta cardiopulmonar normal; PA: 120x80 mmHg; frequência respiratória 30 irpm, pesando 13,5kg, massa abdominal palpável à direita se estendendo da hemicúpula frênica até a linha média do abdome. Solicitados exames complementares. Na TC abdominal foi identificado uma volumosa tumoração renal direita, rechaçando as estruturas adjacentes, com extensão até a hemicúpula frênica. Também foi encontrado um implante secundário na base pulmonar esquerda e um microcálculo na vesícula biliar. USG de abdome total evidenciou uma imagem nodular de contorno lobulado e áreas císticas de permeio, medindo aproximadamente 14x8cm. Nos exames laboratoriais apresentou uma discreta anemia, uma leucocitose com aumento de monócitos, VHS e PCR elevados, EAS com presença de cetona sem hemácias. A criança foi encaminhada à instituição oncológica para a conclusão da investigação e tratamento. Conclusão: Este relato além de oferecer informação atualizada sobre o tumor de Wilms e seus achados de imagem, reforça a necessidade da suspeita e do diagnóstico precoce para o sucesso terapêutico.
APA, Harvard, Vancouver, ISO, and other styles
2

Valdameri, Joana Scapinello, Anna Carolina Flumignan Bucharles, Caroline Baldasso Vieira, Thainá Mirella Macedo, and Maria Luiza Lyczacovski Riesemberg. "CLASSIFICAÇÃO E CARACTERÍSTICAS HISTOLÓGICA DOS CARCINOMAS DE CÉLULAS RENAIS MAIS FREQUENTES." In I Congresso On-line Nacional de Histologia e Embriologia Humana. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/rems/3214.

Full text
Abstract:
Introdução: O carcinoma de células renais (CCR), tumor frequente na população, é caracterizado pelo aumento de massa no parênquima renal, onde encontram-se as unidades funcionais do rim. Sua nova classificação, publicada em 2016 pela WHO (World Health Organization), é baseada em aspectos histológicos que variam conforme os subtipos. Objetivos: Identificar histopatologicamente os principais subtipos de carcinomas de células renais, evidenciando melhor decisão de terapia para melhor prognóstico. Material e métodos: A metodologia consistiu em uma revisão literária de artigos publicados em língua inglesa ou portuguesa, nas bases de dados “Pubmed” e "Scielo", no período entre 2018 e 2022. Foram utilizados como descritores “carcinoma real” e “histologia de carcinoma", e feito leitura dos artigos de maior relevância, considerando cronologia e local de publicação. Resultados: Por meio da análise dos artigos, foi evidenciado que o CCR está entre os tumores mais frequentes na população, sendo os subtipos mais recorrentes os carcinomas renais das células claras (CCRcc), seguidos pelos tipos papilíferos (CCRp) e cromófobos (CCRc). Sua classificação baseia-se em aspectos histológicos, e sua nomenclatura está associada ao citoplasma típico de células tumorais, bem como características estruturais e morfológicas. O CCRcc, que corresponde entre 65 e 70% dos casos, apresenta prognóstico desfavorável. Possui origem no epitélio do túbulo contorcido proximal e é caracterizado pela presença de células claras devido ao citoplasma eosinofílico rico em lipídios e glicogênio. O CCRp, de origem histológica no néfron distal e epitélio tubular, se caracteriza por um tumor imperceptível à palpação, e é dividido em dois subtipos, um com citoplasma escasso e outro com citoplasma eosinofílico. Por fim, o CCRc se origina de células intercalares dos ductos coletores, sendo menos agressivo e mais comum após 60 anos representa 5% dos CCR, possui prognóstico favorável, com baixa incidência de metástase. Existem, ainda, outros subtipos, porém são menos frequentes em relação aos expostos anteriormente. Conclusão: Diante do exposto, nota-se a importância da classificação histológica dos CCR, facilitando a compreensão da função e da composição dos tecidos lesionados, com o objetivo de realizar o prognóstico e tratamento adequado.
APA, Harvard, Vancouver, ISO, and other styles
3

Pishko, Gregory L., Garrett W. Astary, Thomas H. Mareci, and Malisa Sarntinoranont. "High Resolution DCE-MRI Vascular Characterization of Murine Sarcoma and Human Renal Cell Carcinoma for Computational Modeling." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-193179.

Full text
Abstract:
Non-uniform extravasation from blood vessels, elevated interstitial fluid pressure (IFP), and transport by bulk fluid motion in the extracellular space have all been determined to contribute to the non-uniform tissue distribution of systemically delivered agents in solid tumors. The aforementioned factors can lead to inadequate and uneven uptake in tumor tissue which has been shown to be a major obstacle to macromolecules in clinical cancer therapy [1]. Recently developed computational tumor models have described blood flow either in a single vessel or capillary network with variations in space and time [2]. These studies do not account for heterogeneous tissue transport properties in regions of leakier vessels [3].
APA, Harvard, Vancouver, ISO, and other styles
4

Bull, Joseph L., Andre´s J. Caldero´n, Yun Seok Heo, Dongeun Huh, Nobuyuki Futai, Shuichi Takayama, and J. Brian Fowlkes. "A Microfluidic Model of Cardiovascular Bubble Lodging." In ASME/JSME 2007 5th Joint Fluids Engineering Conference. ASMEDC, 2007. http://dx.doi.org/10.1115/fedsm2007-37446.

Full text
Abstract:
Embolotherapy involves the occlusion of blood flow to tumors to treat a variety of cancers, including renal carcinoma and hepatocellular carcinoma. The accompanying liver cirrhosis makes the treatment of hepatocellular carcinoma by traditional methods difficult. Previous attempts at embolotherapy have used solid emboli. A major difficulty in embolotherapy is restricting delivery of the emboli to the tumor. We are developing a novel minimally invasive gas embolotherapy technique that uses gas bubbles rather than solid emboli. The bubbles originate as encapsulated liquid droplets that are small enough to pass through capillaries. The droplets can be selectively vaporized in vivo by focused high intensity ultrasound to form gas bubbles which are then sufficiently large to lodge in the tumor vasculature. We investigated the dynamics of bubble lodging in microfluidic model bifurcations made of poly(dimethylsiloxane) and in theoretical analyses. The results show that the critical driving pressure below which a bubble will lodge in a bifurcation is significantly less than the driving pressure required to dislodge it. Based these results, we estimate that gas bubbles from embolotherapy can lodge in vessels 20 μm or smaller in diameter, and conclude that bubbles may potentially be used to reduce blood flow to tumor microcirculation.
APA, Harvard, Vancouver, ISO, and other styles
5

Gonçalves, Eduardo Von Muhlen Colini, Valentina Lima Cartaxo Da Silva, and Vinicius Von Muhlen Colini Gonçalves. "HISTOLOGIA DO TUMOR DE WILMS E SEU IMPACTO NO PROGNÓSTICO DA DOENÇA." In I Congresso On-line Nacional de Histologia e Embriologia Humana. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/rems/3211.

Full text
Abstract:
INTRODUÇÃO: O Nefroblastoma, também conhecido como Tumor de Wilms, é o tumor renal mais prevalente na infância. Possivelmente causado pelo desenvolvimento anormal das células renais, apresenta proliferação do blastema metanéfrico com diferenciação tubular e glomerular de forma errônea. A histologia é fator determinante para seu prognóstico. OBJETIVOS: Compreender a alteração histológica no Nefroblastoma e sua utilização para determinação do prognóstico. METODOLOGIA: Revisão de literatura realizada nas bases de dados SCIELO, PUBMED, UpToDate e em livros técnico-científicos. RESULTADOS: Macroscopicamente, o Tumor de Wilms consiste em uma grande massa delimitada que, quando seccionada, possui apresentação parda/cinzenta, com possíveis focos hemorrágicos, necrose e cistificações, além de superfície flácida e uniforme. Enquanto isso, microscópicamente, possui três tipos celulares. As células blastêmicas indiferenciadas possuem núcleo arredondado, homogêneo, hipercromático, com cromatina fina e citoplasma escasso, podendo ser encontradas em grupos tridimensionais ou isoladas. Já as células estromais são mais periféricas e apresentam núcleo aumentado e oval, com pouco citoplasma. Além disso, há assimetria em sua distribuição na zona central. As células epiteliais formam túbulos e glomérulos através do processo de maior diferenciação celular. A histologia do tumor é fator preponderante para a classificação de risco pelo protocolo da Société Internationale d’Oncologie Pédiatrique (SIOP), que relata piora do prognóstico quando há presença de anaplasia, ou seja, perda de diferenciação, organização e função específica da célula. Na anaplasia do nefroblastoma há reconhecimento histológico de núcleos pelo menos três vezes maiores que os das células tumorais adjacentes, hipercromáticos e irregulares, com mitoses multipolares e inequívocas. Ademais, a anaplasia possui relação com a resposta quimioterápica, necessitando ser classificada em focal - confinada a um ou mais focos delimitados do tumor - ou difusa - não localizada e/ou além da cápsula renal. Dentro da classificação de risco da SIOP, o nefroblastoma sem anaplasia ou com anaplasia focal possui risco intermediário, enquanto o nefroblastoma com anaplasia difusa é considerado de alto risco. CONCLUSÃO: O Nefroblastoma apresenta uma citoarquitetura peculiar, tendo células em diferentes graus de diferenciação. A anaplasia interfere diretamente em seu prognóstico, sendo o estudo patológico e histológico de extrema importância para a escolha do tratamento adequado.
APA, Harvard, Vancouver, ISO, and other styles
6

Hamouda, Rawhia S., Mohamed A. Eldosokyl, and Ahmed S. Elhggar. "Radiofrequency Ablation of the Renal Tumors." In 2021 38th National Radio Science Conference (NRSC). IEEE, 2021. http://dx.doi.org/10.1109/nrsc52299.2021.9509810.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wang, Chuanxia, Yuting He, Xiaoming Qi, Ziteng Zhao, Guanyu Yang, Xiaomei Zhu, Shaobo Zhang, Jean-Louis Dillenseger, and Jean-Louis Coatrieux. "BiSC-UNet: A fine segmentation framework for kidney and renal tumor." In 2019 Kidney Tumor Segmentation Challenge: KiTS19. University of Minnesota Libraries Publishing, 2019. http://dx.doi.org/10.24926/548719.013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, Joseph, and Benson Jin. "A 2D U-Net for Automated Kidney and Renal Tumor Segmentation." In 2019 Kidney Tumor Segmentation Challenge: KiTS19. University of Minnesota Libraries Publishing, 2019. http://dx.doi.org/10.24926/548719.089.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Les, T., T. Markiewicz, M. Dziekiewicz, and M. Lorent. "Automatic system for the renal and cancer segmentation in CT images." In 2019 Kidney Tumor Segmentation Challenge: KiTS19. University of Minnesota Libraries Publishing, 2019. http://dx.doi.org/10.24926/548719.092.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Young, A. N., M. B. Amin, J. A. Petros, M. J. Natan, Shuming Nie, and M. D. Wang. "Nanomolecular Histopathology for Renal Tumor Classification." In 2005 IEEE Engineering in Medicine and Biology 27th Annual Conference. IEEE, 2005. http://dx.doi.org/10.1109/iembs.2005.1616516.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Tumore renale"

1

Adamczyk, Lukasz, and Jon Oxley. Pathological classification of renal cell tumours. BJUI Knowledge, January 2016. http://dx.doi.org/10.18591/bjuik.0098.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Adamczyk, Lukasz, Paidamwoyo Gwiti, and Jon Oxley. Pathological classification of renal cell tumours. BJUI Knowledge, May 2020. http://dx.doi.org/10.18591/bjuik.0098.v2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sriram, Renuka, and Betty Diamond. Hyperpolarized 13C MR Markers of Renal Tumor Aggressiveness. Fort Belvoir, VA: Defense Technical Information Center, October 2013. http://dx.doi.org/10.21236/ada599542.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sriram, Renuka. Hyperpolarized 13C MR Markers of Renal Tumor Aggressiveness. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada615065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Paul, Elahna. Biomarkers of Renal Tumor Burden and Progression in TSC. Fort Belvoir, VA: Defense Technical Information Center, September 2012. http://dx.doi.org/10.21236/ada568030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Paul, Elahna. Biomarkers of Renal Tumor Burden and Progression in TSC. Fort Belvoir, VA: Defense Technical Information Center, September 2013. http://dx.doi.org/10.21236/ada591994.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Adamczyk, Lukasz, and Jon Oxley. Pathological classification of non-RCC renal parenchymal tumours. BJUI Knowledge, January 2016. http://dx.doi.org/10.18591/bjuik.0634.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Adamczyk, Lukasz, Paidamwoyo Gwiti, and Jon Oxley. Pathological classification of non-RCC renal parenchymal tumours. BJUI Knowledge, May 2020. http://dx.doi.org/10.18591/bjuik.0634.v2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Zhen. Noninvasive Assessment of Renal Tumor Aggressiveness Using Hyperpolarized 13C MR. Fort Belvoir, VA: Defense Technical Information Center, July 2012. http://dx.doi.org/10.21236/ada566862.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shen, Li. A Novel Tumor Antigen and Foxp3 Dual-Targeting Tumor Cell Vaccine Enhances the Immunotherapy in a Murine Model of Renal Cell Carcinoma. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada615157.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Tumore renale' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography